CI

At a glance

ClinicalIndex Comparison Record
Phase 3Completed· 101 enrolled
Drug / intervention
botulinum toxin Type A (44U) +1 morebiological
Likely dose
botulinum toxin Type A (44U) 44 unitsfrom record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT01797094
NCT01797094Phase 3Completed
CompareCT.gov

BOTOX® in the Treatment of Upper Facial Lines in Japan

Allergan·interventional·Posted Feb 22, 2013·Updated Feb 10, 2015

In Brief

A Phase 3 clinical trial evaluating botulinum toxin Type A (44U) and botulinum toxin Type A (32U) for Upper Facial Rhytides and 3 related conditions. Completed, enrolled 101 participants across 1 site.

Detailed Summary

This study will evaluate the safety and efficacy of BOTOX® (botulinum toxin Type A) for the treatment of upper facial lines (Crow's Feet Lines and Frown Lines).

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsUpper Facial Rhytides, Crow's Feet Lines, Glabellar Lines, Frown Lines
CountriesJapan
Collaborators--

Timeline

Phase 3CompletedFinished
20132014201520162017201820192020202120222023202420252026
First PostedFeb 22, 2013
Enrollment StartFeb 1, 2013
Primary CompletionJul 1, 2013
Study CompletionJul 1, 2014
TodayJul 2, 2026
Enrollment to primary: 5 monthsPosted 13.4 years ago

Interventions

botulinum toxin Type A (44U)biological

44 units botulinum toxin Type A (total dose) per treatment. 24 U injected into bilateral Crow's Feet Line areas and 20 U injected into Frown Line area.

botulinum toxin Type A (32U)biological

32 units botulinum toxin Type A (total dose) per treatment. 12 U injected into bilateral Crow's Feet Line areas and 20 U injected into Frown Line area.